Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 13/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.57 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.49 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.49 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372917 | 1.00 | PNLIP (0.57) | PNLIPS1PR1GCGRACP1PTPN12 | |
| SCHEMBL1372231 | 0.95 | S1PR1 (0.62) | PNLIPS1PR1ACP1PTPN12PTPN13 | |
| SCHEMBL1372228 | 0.95 | S1PR1 (0.62) | PNLIPS1PR1ACP1PTPN12PTPN13 | |
| SCHEMBL1372246 | 0.88 | S1PR1 (0.58) | S1PR1LTA4H | |
| SCHEMBL1372249 | 0.88 | S1PR1 (0.58) | S1PR1LTA4H | |
| SCHEMBL1371594 | 0.82 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1371590 | 0.82 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1372073 | 0.81 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1372071 | 0.81 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1373113 | 0.79 | MITF (0.51) | S1PR1MAPTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102256944-A | Sphingosine-1-phosphate receptor antagonists | EXELIXIS INC | 2011-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | PNLIP 646/4885S1PR1 1/4885GCGR 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.